8.47
price down icon3.97%   -0.35
pre-market  시장 영업 전:  8.70   0.23   +2.72%
loading
전일 마감가:
$8.82
열려 있는:
$8.935
하루 거래량:
31.49M
Relative Volume:
0.90
시가총액:
$8.71B
수익:
$113.29M
순이익/손실:
$-351.47M
주가수익비율:
-21.73
EPS:
-0.3898
순현금흐름:
$-309.19M
1주 성능:
+0.95%
1개월 성능:
-2.64%
6개월 성능:
+210.26%
1년 성능:
+208.00%
1일 변동 폭
Value
$8.40
$9.32
1주일 범위
Value
$8.022
$9.32
52주 변동 폭
Value
$1.83
$12.43

Immunitybio Inc Stock (IBRX) Company Profile

Name
명칭
Immunitybio Inc
Name
전화
(844) 696-5235
Name
주소
3530 JOHN HOPKINS COURT, SAN DIEGO
Name
직원
691
Name
트위터
Name
다음 수익 날짜
2024-11-06
Name
최신 SEC 제출 서류
Name
IBRX's Discussions on Twitter

Compare IBRX vs VRTX, REGN, ALNY, ARGX, ONC

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
IBRX icon
IBRX
Immunitybio Inc
8.47 8.71B 113.29M -351.47M -309.19M -0.3898
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
454.00 115.33B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
732.87 77.48B 14.34B 4.50B 3.77B 41.56
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
312.17 41.40B 3.71B 313.75M 465.38M 2.2571
ARGX icon
ARGX
Argen X Se Adr
663.93 41.09B 4.16B 1.29B 734.26M 19.58
ONC icon
ONC
Beone Medicines Ltd Adr
275.28 30.56B 5.36B 287.73M 924.18M 2.5229

Immunitybio Inc Stock (IBRX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2026-03-12 재개 BTIG Research Buy
2025-05-20 업그레이드 Piper Sandler Neutral → Overweight
2025-03-06 개시 H.C. Wainwright Buy
2025-01-10 개시 BTIG Research Buy
2023-05-12 다운그레이드 Piper Sandler Overweight → Neutral
2022-08-03 개시 Jefferies Buy
모두보기

Immunitybio Inc 주식(IBRX)의 최신 뉴스

pulisher
Mar 22, 2026

ImmunityBio Inc stock surges on promising Phase 3 cancer vaccine data amid biotech rally - AD HOC NEWS

Mar 22, 2026
pulisher
Mar 22, 2026

ImmunityBio, Inc. (NASDAQ:IBRX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Mar 22, 2026
pulisher
Mar 21, 2026

How Investors May Respond To ImmunityBio (IBRX) Securing First Asian Approval For ANKTIVA Via Macau Pathway - Yahoo Finance

Mar 21, 2026
pulisher
Mar 21, 2026

Jim Cramer on ImmunityBio: “That Stock Is Part of the Magical Thinking Era” - Insider Monkey

Mar 21, 2026
pulisher
Mar 21, 2026

Promising Biotech Stocks To Keep An Eye OnMarch 21st - MarketBeat

Mar 21, 2026
pulisher
Mar 20, 2026

BTIG Sees Upside in ImmunityBio, Inc. (IBRX), Cites Strong 2026 ANKTIVA Sales Growth - Insider Monkey

Mar 20, 2026
pulisher
Mar 20, 2026

ImmunityBio (NASDAQ:IBRX) Stock Price Down 4%Should You Sell? - MarketBeat

Mar 20, 2026
pulisher
Mar 20, 2026

ImmunityBio Sees Unusually High Options Volume (NASDAQ:IBRX) - MarketBeat

Mar 20, 2026
pulisher
Mar 20, 2026

First ANKTIVA approval in Asia gives bladder cancer drug a Macau entry - Stock Titan

Mar 20, 2026
pulisher
Mar 20, 2026

ImmunityBio receives approval for ANKTIVA in Macau for bladder cancer - Investing.com

Mar 20, 2026
pulisher
Mar 20, 2026

ImmunityBio receives Macau approval for bladder cancer drug By Investing.com - Investing.com India

Mar 20, 2026
pulisher
Mar 20, 2026

ImmunityBio (IBRX) Is Up 12.8% After NCCN Expands ANKTIVA Bladder Cancer Guideline InclusionWhat's Changed - simplywall.st

Mar 20, 2026
pulisher
Mar 20, 2026

ImmunityBio receives Macau approval for bladder cancer drug - Investing.com

Mar 20, 2026
pulisher
Mar 20, 2026

ImmunityBio announces approval in Macau SAR, China for Anktiva - marketscreener.com

Mar 20, 2026
pulisher
Mar 20, 2026

Immunitybio Announces Approval In Macau SAR, China For Anktiva - TradingView

Mar 20, 2026
pulisher
Mar 20, 2026

IBRX Stock Rises Premarket As Founder Flags Early Anktiva Immune Data — Macau Nod Fuels Bull Case - Stocktwits

Mar 20, 2026
pulisher
Mar 20, 2026

symbol__ Stock Quote Price and Forecast - CNN

Mar 20, 2026
pulisher
Mar 20, 2026

IBRX Stock Set To Snap 2 Weeks In Red: Anktiva Joins Global Blockbusters On Macau Drug List - Stocktwits

Mar 20, 2026
pulisher
Mar 19, 2026

ImmunityBio (NASDAQ:IBRX) Shares Up 3%Should You Buy? - MarketBeat

Mar 19, 2026
pulisher
Mar 19, 2026

ImmunityBio gains as NCCN guidelines include new Anktiva indication - MSN

Mar 19, 2026
pulisher
Mar 19, 2026

After years of delays, new deadline looms in 2028 for drug manufacturing plant in Dunkirk - Buffalo News

Mar 19, 2026
pulisher
Mar 19, 2026

Assessing ImmunityBio (IBRX) Valuation After NCCN ANKTIVA Update And NK Cell Therapy Progress - simplywall.st

Mar 19, 2026
pulisher
Mar 18, 2026

ImmunityBio Inc Trade Ideas — SWB:26CA - TradingView

Mar 18, 2026
pulisher
Mar 18, 2026

ImmunityBio (IBRX) Clinical Trial for Lymphona Drug Follows $505M Convertible Note Change - MSN

Mar 18, 2026
pulisher
Mar 18, 2026

ImmunityBio (NASDAQ:IBRX) Stock Price Up 4.3%Here's Why - MarketBeat

Mar 18, 2026
pulisher
Mar 18, 2026

ImmunityBio (IBRX) Resubmits sBLA to FDA for ANKTIVA in Papillary Bladder Cancer - Insider Monkey

Mar 18, 2026
pulisher
Mar 18, 2026

ImmunityBio (IBRX) climbs 7.3% as firm nears development of 'world bank of NK cells' - MSN

Mar 18, 2026
pulisher
Mar 18, 2026

ImmunityBio Stock Jumps on Big Cancer Breakthrough - TipRanks

Mar 18, 2026
pulisher
Mar 18, 2026

5 Most Buzzing Stocks to Buy with the Highest Upside Potential - Insider Monkey

Mar 18, 2026
pulisher
Mar 18, 2026

ImmunityBio Highlights ANKTIVA Surge, FDA Papillary Filing and Key 2026 Milestones at Conference - MarketBeat

Mar 18, 2026
pulisher
Mar 18, 2026

Heights Capital Management Inc. Purchases New Position in ImmunityBio, Inc. $IBRX - MarketBeat

Mar 18, 2026
pulisher
Mar 17, 2026

IBRX Stock Rises After NCCN Guideline Update Expands ANKTIVA’s UseRetail Expects Sales To Surge - Stocktwits

Mar 17, 2026
pulisher
Mar 17, 2026

Is 28.9% Fall In ImmunityBio (IBRX) Stock A Buying Opportunity? - Trefis

Mar 17, 2026
pulisher
Mar 17, 2026

ImmunityBio's Anktiva Could See More Upside: My Updated Thoughts On Expansion - Seeking Alpha

Mar 17, 2026
pulisher
Mar 17, 2026

ImmunityBio Stock To $6? - Trefis

Mar 17, 2026
pulisher
Mar 17, 2026

ImmunityBio Stock Jumps As New Bladder Cancer Guideline Boosts Anktiva Use - Benzinga

Mar 17, 2026
pulisher
Mar 17, 2026

ImmunityBio Stock Jumps As New Bladder Cancer Guideline Boosts Anktiva Use - Benzinga

Mar 17, 2026
pulisher
Mar 17, 2026

NCCN Guideline Expansion Puts ANKTIVA And ImmunityBio Growth In Focus - Yahoo Finance

Mar 17, 2026
pulisher
Mar 17, 2026

ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include AN - PharmiWeb.com

Mar 17, 2026
pulisher
Mar 17, 2026

Will Anktiva Remain a Key Factor in ImmunityBio’s Revenue Expansion in 2026? - Bitget

Mar 17, 2026
pulisher
Mar 17, 2026

ImmunityBio (NASDAQ:IBRX) Given "Buy" Rating at D. Boral Capital - MarketBeat

Mar 17, 2026
pulisher
Mar 17, 2026

Why Is ImmunityBio (IBRX) Stock Jumping Today? ANKTIVA Gains NCCN Backing - Tokenist

Mar 17, 2026
pulisher
Mar 17, 2026

Will Anktiva Continue to Drive ImmunityBio's Top-Line Growth in 2026? - Yahoo Finance

Mar 17, 2026
pulisher
Mar 17, 2026

NCCN expands bladder cancer guidelines to include ImmunityBio drug - Investing.com

Mar 17, 2026
pulisher
Mar 17, 2026

IBRX Stock Is Rising Pre-Market On This Cancer Treatment Expansion - Stocktwits

Mar 17, 2026
pulisher
Mar 17, 2026

ImmunityBio gains on NCCN guidelines update (IBRX:NASDAQ) - Seeking Alpha

Mar 17, 2026
pulisher
Mar 17, 2026

ImmunityBio, Inc. (NASDAQ: IBRX) announced today that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology have been updated to officially include Anktiva (generic name: N-803) in combination with BCG as a treat - Bitget

Mar 17, 2026
pulisher
Mar 17, 2026

Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA - Business Wire

Mar 17, 2026
pulisher
Mar 17, 2026

IBRX Stock Rises Overnight: Retail Bets Anktiva’s NCCN 'Recommended' Tag Will Drive Prescriptions And Insurance Wins - Stocktwits

Mar 17, 2026
pulisher
Mar 16, 2026

IBRX stock jumps on progress in NK cell therapy production - MSN

Mar 16, 2026
pulisher
Mar 16, 2026

ImmunityBio (NASDAQ:IBRX) Stock Price Down 2.1%Here's What Happened - MarketBeat

Mar 16, 2026

Immunitybio Inc (IBRX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$45.36
price down icon 0.37%
$27.70
price down icon 0.36%
$51.38
price down icon 1.89%
$89.27
price down icon 0.04%
$136.00
price down icon 5.56%
ONC ONC
$275.28
price down icon 2.63%
자본화:     |  볼륨(24시간):